Apolipoprotein E ε4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease

American Journal of Neuroradiology

Volumn 34, Issue 3, 2013, Pages 505-510

  Desikan, R S ^a   McEvoy, L K ^a   Holland, D ^a   Thompson, W K ^a   Brewer, J B ^a   Aisen, P S ^a   Andreassen, O A ^a,b   Hyman, B T ^c   Sperling, R A ^c   Dale, A M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; AMYLOID; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT; TAU PROTEIN;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN REGION; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENTORHINAL CORTEX; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; NERVE DEGENERATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN CEREBROSPINAL FLUID LEVEL; PUNCTURE; BRAIN; FEMALE; MALE; METABOLISM; METHODOLOGY; PATHOLOGY; TISSUE DISTRIBUTION;

AGED; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; BRAIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PEPTIDE FRAGMENTS; TAU PROTEINS; TISSUE DISTRIBUTION;

EID: 84876583747     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3267     Document Type: Article

References (31)

1. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 2011;17:1060-65
2. Spires-Jones TL, Meyer-Luehmann M, Osetek JD, et al. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol 2007;171:1304-11
3. Kuchibhotla KV, Goldman ST, Lattarulo CR, et al. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 2008;59:214-25
4. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis-APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-56
5. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoformdependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2000;97:2892-97
6. Deane R, Sagare A, Hamm K, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 2008;118:4002-13
7. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007;316:750-54
8. Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010;142:387-97
9. Morris JC. Early-stage and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord 2005;19:163-65
10. Storandt M, Mintun MA, Head D, et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009;66:1476-81
11. Ewers M, Insel P, Jagust WJ, et al. CSF biomarker and PIB-PETderived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex 2012;22:1993-2004
12. Chételat G, Villemagne VL, Villain N, et al. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 2012;78:477-84
13. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-92
14. Desikan RS, McEvoy LK, Thompson W, et al. Amyloid-βassociated volume loss occurs only in the presence of phospho-tau. Ann Neurol 2011;70:657-61
15. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-13
16. Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968-80
17. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
18. Arnold SE, Hyman BT, Flory J, et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1991;1:103-16
19. Gómez-Isla T, Price JL, McKeel DW Jr, et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996;16:4491-500
20. Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 2001;49:202-13
21. Holland D, Dale AM. Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal 2011;15:489-97
22. Ittner LM, Gotz J. Amyloid-βand tau: a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011;12:65-72
23. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009;64:632-44
24. Schott JM, Bartlett JW, Fox NC, et al. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol 2010;68:825-34
25. Becker JA, Hedden T, Carmasin J, et al. Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol 2011;69:1032-42
26. Kantarci K, Lowe V, Przybelski SA, et al. APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology 2012;78:232-40
27. Sunderland T, Mirza N, Putnam KT, et al. Cerebrospinal fluid betaamyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 2004;56:670-76
28. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122-31
29. Desikan RS, McEvoy LK, Thompson WK, et al. Amyloid-β-associated clinical decline occurs only in the presence of elevated p-tau. Arch Neurol 2012;69:709-13
30. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011;3:77sr1
31. Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011;68:1062-64